Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 9Other hematologic neoplasm 8Classical hematology 2Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 5Anemia, Refractory, with Excess of Blasts 5Leukemia, Myeloid, Acute 4Anemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hematologic Neoplasms 2Cytopenia 2Congenital Abnormalities 2Thrombocytosis 1Thrombocytopenia 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neoplastic Syndromes, Hereditary 1Neoplasm Metastasis 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 22fludarabine phosphate 18Busulfan 16Antilymphocyte Serum 15Radiotherapy 12Cyclosporine 11Cord Blood Stem Cell Transplantation 11Peripheral Blood Stem Cell Transplantation 10Melphalan 10Filgrastim 10Tacrolimus 9Mycophenolic Acid 9Methylprednisolone 9Methotrexate 9Etoposide 7Cytarabine 7Whole-Body Irradiation 6sargramostim 4Tretinoin 3Thalidomide 3Carboplatin 3venetoclax 2ruxolitinib 2Thiotepa 2Thioguanine 2Specimen Handling 2Sirolimus 2Rituximab 2Leucovorin 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × Biopsy × Classical hematology × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT00425477 2018-10-05

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
26 enrolled 7 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡